Recent studies have proposed that IL-17A could act as a potential treatment option for pancreatic cancer by crossing a mouse model of idiopathic PDAC (KPC) with IL-17A knockout mice and that cells with intact IL-17A and IL-17A-deficient cells had very different characteristics [14]. The gene discussed is IL17A; the disease is familial pancreatic carcinoma.